Pfizer plans 20 pivotal studies and four regulatory decisions in 2026

“On Pfizer's first-quarter earnings call, CEO Albert Bourla was optimistic that in 2029, the company will begin a five-year period of strong growth, with revenue growth rates in the high…”

“We intend to maintain and over time, grow our dividend as we continue to delever and build long-term value.”

“He replied that Pfizer will always explore merger and acquisition opportunities, but the company isn't planning to pursue a large-scale merger. Bourla added that the disruption of a mega…”

“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”

“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”

“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”